Document:

THIS NOTE AND THE CONVERSION SHARES
ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES
LAWS. THIS NOTE AND THE CONVERSION SHARES ISSUABLE UPON CONVERSION OF THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED
IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS NOTE UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS
OR (B) AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS. 

 

SECURED CONVERTIBLE TERM NOTE

 

FOR VALUE RECEIVED, HEALTHCARE CORPORATION
OF AMERICA, a Delaware corporation (the “Company”) hereby promises to pay to [___________] (the “Holder”)
or its registered assigns or successors in interest, the sum of [___________] ($[_______]) (the “Original Principal Amount”),
plus all PIK Amounts (as hereinafter defined) added to the principal amount hereof pursuant to the terms of this Note (as hereinafter
defined), together with any accrued and unpaid interest hereon and any and all other sums due, accrued or payable to the Holder
arising under this Note, the Purchase Agreement or any other agreements and ancillary documents in respect thereof, including without
limitation, the Security Agreement, the Guaranty, and related subordination agreements (collectively, the “Related Agreements”),
on April 2, 2015 (the “Maturity Date”), if not sooner indefeasibly paid in full.

 

This Secured Convertible Note (including all
Secured Convertible Notes issued in exchange, transfer or replacement hereof, this “Note”) is one of an issue
of Secured Convertible Notes issued pursuant to the Purchase Agreement (as defined below) on the Closing Date (as defined below)
(collectively, the “Note,” and such other Secured Convertible Notes in connection with the Purchase Agreement,
the “other Notes”). Certain capitalized terms used herein are defined in Section 5.15, and others used herein
without definition shall have the meanings ascribed to such terms in that certain Purchase Agreement dated as of the date hereof
(as amended, restated, modified and/or supplemented from time to time, the “Purchase Agreement”) among the Company,
the Holder and each other Purchaser (collectively, the “Creditor Parties”), as well as the Security Agreement
entered into in connection herewith by the Company, the Holder (or on its behalf), and the Subsidiary of the Company, 340 Basics,
Inc (the “Security Agreement”), as well as the Guaranty entered into by 340 Basics, Inc. in respect of the Company’s
obligations under the Purchase Agreement (the “Guaranty”).

 

		1	INTEREST; CONVERSION; PREPAYMENT

 

1.1             
Interest. Unless otherwise provided herein, interest payable on the outstanding principal amount of this Note, including
all PIK Amounts added thereto through such time (the “Accreted Principal Amount”) shall accrue at a rate per
annum equal to eight percent (8%). Accrued and unpaid interest shall be payable in arrears on the first day of each month (each,
an “Interest Payment Date”) and shall be payable in cash; provided, however, at the election of the Company,
any portion of the interest due and payable on an Interest Payment Date may be paid by adding the amount of such interest due to
the then outstanding Accreted Principal Amount (such capitalized Interest, a “PIK Amount”). Interest on this
Note shall accrue from the date of issuance until repayment of the Accreted Principal Amount and payment of all accrued interest
in full. Interest shall accrue and be computed on the basis of the actual number of days in the related period over 360 days.

 

1.2             
Optional Redemption by the Company. The Company may prepay this Note or a portion thereof (the “Optional
Redemption”) by paying to the Holders, in aggregate, a sum of money equal to at least one hundred thousand dollars ($100,000)
out of the Accreted Principal Amount outstanding at such time together with accrued but unpaid interest thereon and any and all
other sums due, accrued or payable to the Holder arising under this Note, the Purchase Agreement or any other Related Agreement
(the “Redemption Amount”) outstanding on the Redemption Payment Date (as defined below). The Company shall deliver
to the Holder a written notice of redemption (the “Notice of Redemption”) specifying the date for such Optional
Redemption (the “Redemption Payment Date”), which date shall be not less than thirty (30) days after the date
of the Notice of Redemption (the “Redemption Period”). On the Redemption Payment Date, the Redemption Amount
must be paid in good funds to the Holder. In the event the Company fails to pay the Redemption Amount on the Redemption Payment
Date as set forth herein, then such Redemption Notice will be null and void. If other Notes are outstanding and the Company elects
to make an Optional Redemption, then the Company shall pay the Redemption Amount outstanding on all such other Notes on a pro rata
basis.

 

    	 

    	-2-

    

 

1.3             
Optional Conversion by the Holder.

 

(a)               
Conversion. The Holder may elect to convert this Note into validly issued, fully paid and non-assessable shares of
Common Stock of the Company (“Conversion Shares”). The number of Conversion Shares to be received by any Holder
in connection with such conversion shall be an amount, as may be adjusted pursuant to Section 1.6 of this Note, determined by dividing
(x) the sum of the outstanding Accreted Principal Amount and/or accrued interest and fees due or accrued and payable to such Holder
arising under this Note (the “Conversion Amount”) by (y) lowest price per share offered for the Next Round Securities
(as defined in the Purchase Agreement) (the “Conversion Price”). The Holder shall have the right, but not the
obligation, to convert all or part of the issued and outstanding Accreted Principal Amount and/or accrued interest and fees due
and payable into Conversion Shares at the Conversion Price, at any time from time to time while this Note is outstanding following
notice of the Next Financing Round (as defined in the Purchase Agreement), upon two business days’ notice, elect to convert
this Note into Conversion Shares. In the event that the Holder elects to convert this Note into Conversion Shares, the Holder shall
deliver (whether via facsimile or otherwise), for receipt on or prior to 5:30 p.m., New York time, on any Trading Day, a copy of
an executed notice of conversion in the form attached hereto as Exhibit I (the “Conversion Notice”) to the Company.
A Conversion Notice delivered after such time or on a non-Trading Day shall be deemed to have been delivered on the following Trading
Day. If required by Section 1.3(c), within three (3) Trading Days following a conversion of this Note as aforesaid, the Holder
shall surrender this Note to a nationally recognized overnight delivery service for delivery to the Company. On or before the first
(1st) Trading Day following the date of receipt of a Conversion Notice (whether via facsimile or otherwise), the Company shall
transmit by facsimile an acknowledgment of confirmation, in the form attached hereto as Exhibit II, of receipt of such Conversion
Notice to the Holder and the Company’s transfer agent (the “Transfer Agent”) and shall promptly instruct
and otherwise use its reasonable best efforts to cause the Transfer Agent to complete the following actions on or before the second
(2nd) Trading Day following the date of receipt of a Conversion Notice (whether via facsimile or otherwise): (1) provided that
the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer
Program and provided that the shares issued pursuant to such exercise have been sold pursuant to a bona fide sale under Rule 144,
a registration statement or an exemption from registration, upon the request of the Holder, credit such aggregate number of shares
of Common Stock to which the Holder is entitled pursuant tosuch exercise to the Holder’s designee’s balance account
with DTC through its Deposit/Withdrawal at Custodian system, or (2) issue and deliver (via reputable overnight courier) to the
address as specified in the Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number
of shares of Common Stock to which the Holder shall be entitled. If this Note is physically surrendered for conversion pursuant
to Section 1.3(c) and the outstanding Accreted Principal Amount of this Note is greater than the Accreted Principal Amount portion
of the Conversion Amount being converted, then the Company shall as soon as practicable and in no event later than three (3) Business
Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its designee) a new Note (in accordance
with Section 1.3(c) representing the outstanding Accreted Principal Amount not converted. The Person or Persons entitled to receive
the shares of Common Stock issuable upon a conversion of this Note shall be treated for all purposes as the record holder or holders
of such shares of Common Stock on the Conversion Date. The Holder shall be treated for all purposes as the record holder of the
Conversion Shares unless the Holder provides the Company written instructions to the contrary.

 

    	 

    	-3-

    

 

(b)              
Company’s Failure to Timely Convert. If the Company shall fail, for any reason or for no reason, on the first
(1st) Trading Day immediately following the Company’s receipt of a Conversion Notice (whether via facsimile or otherwise)
from a Holder, to give notice to and instruct, and otherwise use the Company’s reasonable best efforts to cause, the Transfer
Agent to thereafter promptly issue to such Holder a certificate for the number of shares of Common Stock to which the Holder is
entitled and register such shares of Common Stock on the Company’s share register or to credit the Holder’s or its
designee’s balance account with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder’s
conversion of any Conversion Amount (as the case may be) (a “Conversion Failure”), then, in addition to all
other remedies available to the Holder, the Holder may declare the Company to be in default under this Note. Furthermore, (1) the
Company shall pay in cash to the Holder on each Trading Day after such third (3rd) Trading Day that the issuance of such shares
of Common Stock is not timely effected an amount equal to 1% of the product of (A) the sum of the number of shares of Common Stock
not issued to the Holder on a timely basis and to which the Holder is entitled multiplied by (B) the Closing Sale Price of the
Common Stock on the Trading Day immediately preceding the last possible date which the Company could have issued such shares of
Common Stock to the Holder without violating Sections 1.3(a) and (b) the Holder, upon written notice to the Company, may void its
Conversion Notice with respect to, and retain or have returned (as the case may be) any portion of this Note that has not been
converted pursuant to such Conversion Notice, provided that the voiding of a Conversion Notice shall not affect the Company’s
obligations to make any payments which have accrued prior to the date of such notice pursuant to this Section 1.3(b) or otherwise.
In addition to the foregoing, if within three (3) Trading Days after the Company’s receipt of a Conversion Notice (whether
via facsimile or otherwise), the Company shall fail to issue and deliver a certificate to the Holder and register such shares of
Common Stock on the Company’s share register or credit the Holder’s designee’s balance account with DTC for the
number of shares of Common Stock to which the Holder is entitled upon the Holder’s conversion hereunder (as the case may
be), and if on or after such third (3rd) Trading Day the Holder (or any other Person in respect, or on behalf, of the Holder) purchases
(in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or
any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion
of the number of shares of Common Stock, issuable upon such conversion that the Holder so anticipated receiving from the Company,
then, in addition to all other remedies available to the Holder, the Company shall, within three (3) Business Days after the Holder’s
request and in the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total
purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased
(including, without limitation, by any other Person in respect, or on behalf, of the Holder) (the “Buy-In Price”),
at which point the Company’s obligation to so issue and deliver such certificate or credit the Holder’s designee’s
balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder’s conversion
hereunder (as the case may be) (and to issue such shares of Common Stock) shall terminate, or (ii) promptly honor its obligation
to so issue and deliver to the Holder a certificate or certificates representing such shares of Common Stock for the number of
shares of Common Stock or credit the Holder’s designee’s balance account with DTC to which the Holder is entitled upon
the Holder’s conversion hereunder (as the case may be) and pay cash to the Holder in an amount equal to the excess (if any)
of the Buy-In Price over the product of (A) such number of shares of Common Stock multiplied by (B) the lowest Closing Sale Price
of the Common Stock on any Trading Day during the period commencing on the date of the applicable Conversion Notice and ending
on the date of such issuance and payment under this Section 1.3.

 

    	 

    	-4-

    

 

(c)               
Registration; Book-Entry. The Company shall maintain a register (the “Register”) for the recordation
of the names and addresses of the holders of each Note and the Accreted Principal Amount of the Notes held by such holders (the
“Registered Notes”). The entries in the Register shall be conclusive and binding for all purposes absent manifest
error. The Company and the holders of the Notes shall treat each Person whose name is recorded in the Register as the owner of
a Note for all purposes (including, without limitation, the right to receive payments hereunder, including payments of Accreted
Principal Amount and interest) notwithstanding notice to the contrary. A Registered Note may be assigned, transferred or sold in
whole or in part only by registration of such assignment or sale on the Register. Upon its receipt of a request to assign, transfer
or sell all or part of any Registered Note by the holder thereof, the Company shall record the information contained therein in
the Register and issue one or more new Registered Notes in the same aggregate Accreted Principal Amount as the Accreted Principal
Amount of the surrendered Registered Note to the designated assignee or transferee pursuant to Article IV, provided that if the
Company does not so record an assignment, transfer or sale (as the case may be) of all or part of any Registered Note within two
(2) Business Days of such a request, then the Register shall be automatically updated to reflect such assignment, transfer or sale
(as the case may be). Notwithstanding anything to the contrary set forth in this Article I, following conversion of any portion
of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Company
unless (A) the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered
to the Company following conversion thereof) or (B) the Holder has provided the Company with prior written notice (which notice
may be included in a Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. The Holder and
the Company shall maintain records showing the Accreted Principal Amount, interest and default interest converted and/or paid (as
the case may be) and the dates of such conversions and/or payments (as the case may be) or shall use such other method, reasonably
satisfactory to the Holder and the Company, so as not to require physical surrender of this Note upon partial conversion.

 

1.4             
Pro Rata Conversion; Disputes. In the event that the Company receives a Conversion Notice from more than one holder
of Notes for the same Conversion Date and the Company can convert some, but not all, of such portions of the Notes submitted for
conversion, the Company shall convert from each holder of Notes electing to have Notes converted on such date a pro rata amount
of such holder’s portion of its Notes submitted for conversion based on the Accreted Principal Amount of Notes submitted
for conversion on such date by such holder relative to the aggregate Accreted Principal Amount of all Notes submitted for conversion
on such date. In the event of a dispute as to the number of shares of Common Stock issuable to the Holder in connection with a
conversion of this Note, the Company shall issue to the Holder the number of shares of Common Stock not in dispute and resolve
such dispute in accordance with Section 5.10.

 

1.5             
Fractional Shares. The Company shall not issue any fraction of a share of Common Stock upon any conversion. If the
issuance would result in the issuance of a fraction of a share of Common Stock, the Company shall round such fraction of a share
of Common Stock up to the nearest whole share. The Company shall pay any and all transfer, stamp, issuance and similar taxes that
may be payable with respect to the issuance and delivery of Common Stock upon conversion of any Conversion Amount.

 

1.6             
Adjustment Provisions. Reserved.

 

1.7             
Rights upon Fundamental Transaction. Reserved.

 

1.8             
Reservation of Shares. The Company shall in connection with the Next Financing Round (as defined in the Purchase
Agreement) reserve out of its authorized and unissued Common Stock a number of shares of Common Stock for each of the Notes equal
to 125% of the number of shares of Common Stock as shall from time to time be necessary to effect the conversion of all of the
Notes as of the Issuance Date. So long as any of the Notes are outstanding, the Company shall take all action necessary to reserve
and keep available out of its authorized and unissued Common Stock, solely for the purpose of effecting the conversion of the Notes,
125% of the number of shares of Common Stock as shall from time to time be necessary to effect the conversion of all of the Notes
then outstanding, provided that at no time shall the number of shares of Common Stock so reserved be less than the number of shares
required to be reserved by the previous sentence (the “Required Reserve Amount”). The initial number of shares
of Common Stock reserved for conversions of the Notes and each increase in the number of shares so reserved shall be allocated
pro rata among the holders of the Notes based on the original Accreted Principal Amount of the Notes held by each holder on the
Closing Date or increase in the number of reserved shares (as the case may be) (the “Authorized Share Allocation”).
In the event that a Holder shall sell or otherwise transfer any of such Holder’s Notes, each transferee shall be allocated
a pro rata portion of such Holder’s Authorized Share Allocation. Any shares of Common Stock reserved and allocated to any
Person which ceases to hold any Notes shall be allocated to the remaining Holders of Notes, pro rata based on the Accreted Principal
Amount of the Notes then held by such Holders.

 

    	 

    	-5-

    

 

1.9             
Insufficient Authorized Shares. If, notwithstanding Section 1.8, and not in limitation thereof, at any time while
any of the Notes remain outstanding the Company, and in connection with the Next Financing Round (as defined the Purchase Agreement),
does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for
issuance upon conversion of the Notes at least a number of shares of Common Stock equal to the Required Reserve Amount (an “Authorized
Share Failure”), then the Company shall immediately take all action necessary to increase the Company’s authorized
shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for the Notes then outstanding.
Without limiting the generality of the foregoing sentence, to the extent required by law or the rules of the Eligible Market on
which the Common Stock is traded or quoted, as soon as practicable after the date of the occurrence of an Authorized Share Failure,
but in no event later than sixty (60) days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting
of its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such
meeting, to the extent required by law or the rules of the Eligible Market on which the Common Stock is traded or quoted, the Company
shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders’ approval
of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that
they approve such proposal. Notwithstanding the foregoing, subject to applicable law and the rules of the Eligible Market, if the
Company is able to increase its authorized share capital other than by a meeting no later than sixty (60) days after the occurrence
of such Authorized Share Failure, it shall not be require to hold a meeting of its stockholders as provided in this Section 1.9.

 

1.10         
No Rights of Shareholder. No Holder shall be entitled to vote or receive dividends or be deemed the holder of the
Conversion Shares or any other securities of the Company which may at any time be issuable upon conversion of this Note for any
purpose, nor shall anything contained herein be construed to confer upon the Holder, as such, any of the rights of a shareholder
of the Company or any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof,
or to give or withhold consent to any corporate action (whether upon the recapitalization, issuance of shares, reclassification
of shares, change of nominal value, consolidation, merger, conveyance or otherwise) or to receive notice of meetings, or to receive
dividends or subscription rights or otherwise, in each case, until the Delivery Date applicable to the respective Conversion Shares
purchasable upon the conversion hereof shall have occurred as provided herein.

 

1.11         
Conversion Shares. The Company represents that upon issuance, the Conversion Shares will be duly and validly issued,
fully paid and non-assessable. The Company agrees that its issuance of this Note shall constitute full authority to its officers,
agents, and transfer agents who are charged with the duty of executing and issuing stock certificates to execute and issue the
necessary certificates for the Conversion Shares upon the conversion of this Note. In respect of the Conversion Shares, the Company
agrees to grant the Holder the same registration rights applicable in accordance with that certain Registration Rights Agreement,
dated as of December 2013, by and among the Company and the investors named therein, or if there exists a newer Registration Rights
Agreement, then the most recent version thereof.

 

    	 

    	-6-

    

 

		2	EVENTS OF DEFAULT

 

2.1             
Events of Default. The occurrence of an Event of Default (as defined in the Security Agreement) shall constitute
an event of default (“Event of Default”) hereunder.

 

2.2             
Default Interest. Following the occurrence and during the continuance of an Event of Default, the Company shall pay
additional interest on the outstanding Accreted Principal Amount balance of this Note in an amount equal to two percent (2%) per
annum, and all outstanding obligations under this Note, the Purchase Agreement and each other Related Agreement, including unpaid
interest, shall continue to accrue interest at such additional interest rate from the date of such Event of Default until the date
such Event of Default is cured or waived.

 

2.3             
Notice of an Event of Default; Redemption Right. Upon the occurrence of an Event of Default with respect to this
Note or any other Note, the Company shall within one (1) Business Day deliver written notice thereof via facsimile and overnight
courier (with next day delivery specified) (an “Event of Default Notice”) to the Holder. At any time after the
earlier of the Holder’s receipt of an Event of Default Notice and the Holder becoming aware of an Event of Default, the Holder
may require the Company to redeem (regardless of whether such Event of Default has been cured) all or any portion of this Note
by delivering written notice thereof (the “Event of Default Redemption Notice”) to the Company, which Event
of Default Redemption Notice shall indicate the portion of this Note the Holder is electing to redeem.

 

		3	COVENANTS

 

3.1             
Until all of the Notes have been converted, redeemed or otherwise satisfied in accordance with their terms:

(a)               
Rank. All payments due under this Note shall rank pari passu with all other Notes in respect of the Purchase Agreement,
and be senior to all other Indebtedness (as such term is defined in the Security Agreement) of the Company and its Subsidiaries,
except as otherwise set forth in the Related Agreements.

 

(b)              
Incurrence of Indebtedness. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly
or indirectly, incur or guarantee, assume or suffer to exist any Indebtedness other than as is permitted under the Security Agreement.

 

(c)               
Existence of Liens. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly
or indirectly, allow or suffer to exist any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any
property or assets (including accounts and contract rights) owned by the Company or any of its Subsidiaries (collectively, “Liens”)
other than in accordance and as explicitly permissible under the Security Agreement.

 

(d)              
Restricted Payments. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly
or indirectly, prepay, by the payment of cash or cash equivalents (in whole or in part, whether by way of open market purchases,
tender offers, private transactions or otherwise), all or any portion of any Indebtedness except as otherwise set forth in the
Security Agreement.

 

(e)               
Restriction on Redemption and Cash Dividends. The Company shall not, directly or indirectly, redeem, repurchase or
declare or pay any cash dividend or distribution on any of its capital stock other than as is set forth in the Security Agreement.

 

(f)               
Restriction on Transfer of Assets. The Company shall not, and the Company shall cause each of its Subsidiaries to
not, directly or indirectly, sell, lease, license, assign, transfer, convey or otherwise dispose of any assets or rights of the
Company or any Subsidiary (including the securities of any Subsidiary) owned or hereafter acquired whether in a single transaction
or a series of related transactions, other than as set forth in the Security Agreement.

 

    	 

    	-7-

    

 

(g)               
Change in Nature of Business. The Company shall not, and the Company shall cause each of its Subsidiaries to not,
directly or indirectly, engage in any material line of business substantially different from those lines of business conducted
by the Company and each of its Subsidiaries on the date hereof or any business substantially related or incidental thereto. The
Company shall not, and the Company shall cause each of its Subsidiaries to not, directly or indirectly, modify its or their corporate
structure or purpose.

 

(h)              
Noncircumvention. The Company hereby covenants and agrees that the Company will not, by amendment of its Charter,
Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale
of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Note, and will at all times in good faith carry out all of the provisions of this Note and take all action as may be required to
protect the rights of the Holder of this Note. Without limiting the generality of the foregoing, the Company (i) shall not increase
the par value of any shares of Common Stock receivable upon conversion of this Note above the Conversion Price then in effect,
(ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully
paid and non-assessable shares of Common Stock upon the conversion of this Note, and (iii) shall, so long as any of the Notes are
outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock,
solely for the purpose of effecting the conversion of the Notes, the maximum number of shares of Common Stock as shall from time
to time be necessary to effect the conversion of the Notes then outstanding.

 

(i)                
Guaranties and Security. This Note and the other Notes are secured to the extent and in the manner set forth in the
Purchase Agreement and the Related Agreements (including, without limitation, the Security Agreement and the Guaranty).

 

		4	REISSUANCE OF NOTE

 

4.1             
Transfer. If this Note is to be transferred, the Holder shall surrender this Note to the Company, whereupon the Company
will forthwith issue and deliver upon the order of the Holder a new Note, registered as the Holder may request, representing the
outstanding Accreted Principal Amount being transferred by the Holder and, if less than the entire outstanding amount is being
transferred, a new Note to the Holder representing the outstanding Accreted Principal Amount not being transferred. The Holder
and any assignee, by acceptance of this Note, acknowledge and agree that, following conversion or redemption of any portion of
this Note, the outstanding Accreted Principal Amount represented by this Note may be less than the Accreted Principal Amount stated
on the face of this Note.

 

4.2             
Lost, Stolen or Mutilated Note. Upon receipt by the Company of evidence reasonably satisfactory to the Company of
the loss, theft, destruction or mutilation of this Note (as to which a written certification and the indemnification contemplated
below shall suffice as such evidence), and, in the case of loss, theft or destruction, of any indemnification undertaking by the
Holder to the Company in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of this
Note, the Company shall execute and deliver to the Holder a new Note representing the then outstanding Accreted Principal Amount
of this Note.

 

4.3             
Note Exchangeable for Different Denominations. This Note is exchangeable, upon the surrender hereof by the Holder
at the Accreted Principal Amount office of the Company, for a new Note or Notes (in principal amounts of at least $1,000) representing
in the aggregate the then outstanding Accreted Principal Amount of this Note, and each such new Note will represent such portion
of such outstanding Accreted Principal Amount as is designated by the Holder at the time of such surrender.

 

    	 

    	-8-

    

 

4.4             
Issuance of New Notes. Whenever the Company is required to issue a new Note pursuant to the terms of this Note, such
new Note (i) shall be of like tenor with this Note, (ii) shall represent, as indicated on the face of such new Note, the Accreted
Principal Amount remaining outstanding at that time (or in the case of a new Note being issued, the Accreted Principal Amount designated
by the Holder which, when added to the Accreted Principal Amount represented by the other new Notes issued in connection with such
issuance, does not exceed the Accreted Principal Amount remaining outstanding under this Note immediately prior to such issuance
of new Notes), (iii) shall have an issuance date, as indicated on the face of such new Note, which is the same as the Issuance
Date of this Note, (iv) shall have the same rights and conditions as this Note, and (v) shall represent accrued and unpaid Interest
and default interest on the Accreted Principal Amount of this Note, from the Issuance Date.

 

		5	MISCELLANEOUS

 

5.1             
Conversion Privileges. The conversion privileges set forth herein shall remain in full force and effect immediately
from the date hereof until the date this Note is indefeasibly paid in full and irrevocably terminated.

 

5.2             
Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief. The remedies provided in this Note
shall be cumulative and in addition to all other remedies available under this Note and any of the Purchase Agreement and Related
Agreements at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein
shall limit the Holder’s right to pursue actual damages for any failure by the Company to comply with the terms of this Note.
The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly
provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation
thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any
other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder
will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore
agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available
remedies, to an injunction restraining any such breach or any such threatened breach, without the necessity of showing economic
loss and without any bond or other security being required. The Company shall provide all information and documentation to the
Holder that is requested by the Holder to enable the Holder to confirm the Company’s compliance with the terms and conditions
of this Note.

 

5.3             
Failure or Indulgence Not Waiver. No failure or delay on the part of the Holder in the exercise of any power, right
or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or
privilege preclude other or further exercise thereof or of any other right, power or privilege. No waiver shall be effective unless
it is in writing and signed by an authorized representative of the waiving party.

 

5.4             
Notices. Any notice herein required or permitted to be given shall be given in writing in accordance with the terms
of the Purchase Agreement.

 

5.5             
Amendment. Provisions of this Note may be amended only with the written consent of the Company and the Required Holders.
Any amendment effected in accordance with this Section 5.5 shall be binding upon the Holder and the Company, provided that no such
amendment shall be effective to the extent that it (a) applies to less than all of the holders of Notes, (b) imposes any obligation
or liability on the Holder without the Holder’s prior written consent (which may be granted or withheld in the Holder’s
sole discretion) or (c) applies retroactively. The term “Note” and all references thereto, as used throughout
this instrument, shall mean this instrument as originally executed, or if later amended or supplemented, then as so amended or
supplemented, and any successor instrument as such successor instrument may be amended or supplemented.

 

    	 

    	-9-

    

 

5.6             
Transfer; Assignability. This Note and any shares of Common Stock issued upon conversion of this Note may be offered,
sold, assigned or transferred by the Holder without the consent of the Company, subject only to the applicable provisions of the
Purchase Agreement and subject to the Holder delivering written notice to the Company of all information relating to any subsequent
purchaser, assignee or transferee of the Note so that the Company may keep an accurate record of all the then current holders of
the Notes. This Note shall be binding upon the Company and its successors and assigns, and shall inure to the benefit of the Holder
and its successors and assigns. The Company may not assign any of its obligations under this Note without the prior written consent
of the Holder, any such purported assignment without such consent being null and void.

 

5.7             
Waiver of Notice. To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment,
protest and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this
Note and the Purchase Agreement.

 

5.8             
Payment of Collection, Enforcement and Other Costs. If (a) this Note is placed in the hands of an attorney for collection
or enforcement or is collected or enforced through any legal proceeding or the Holder otherwise takes action to collect amounts
due under this Note or to enforce the provisions of this Note or (b) there occurs any bankruptcy, reorganization, receivership
of the Company or other proceedings affecting Company creditors’ rights and involving a claim under this Note, then the Company
shall pay the costs incurred by the Holder for such collection, enforcement or action or in connection with such bankruptcy, reorganization,
receivership or other proceeding, including, without limitation, reasonable attorneys’ fees and disbursements.

 

5.9             
Governing Law, Jurisdiction and Waiver of Jury Trial.

 

(a)               
THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT
REGARD TO PRINCIPLES OF CONFLICTS OF LAW.

 

(b)              
THE COMPANY HEREBY CONSENTS AND AGREES THAT THE STATE AND/OR FEDERAL COURTS LOCATED IN THE COUNTY OF NEW YORK, STATE OF
NEW YORK SHALL HAVE EXCLUSIVE JURISDICTION TO HEAR AND DETERMINE ANY CLAIMS OR DISPUTES BETWEEN THE COMPANY, ON THE ONE HAND, AND
THE HOLDER AND/OR ANY OTHER CREDITOR PARTY, ON THE OTHER HAND, PERTAINING TO THIS NOTE OR ANY OF THE OTHER RELATED AGREEMENTS OR
TO ANY MATTER ARISING OUT OF OR RELATED TO THIS NOTE OR ANY OF THE RELATED AGREEMENTS; PROVIDED, THAT THE COMPANY ACKNOWLEDGES
THAT ANY APPEALS FROM THOSE COURTS MAY HAVE TO BE HEARD BY A COURT LOCATED OUTSIDE OF THE COUNTY OF NEW YORK, STATE OF NEW YORK;
AND FURTHER PROVIDED, THAT NOTHING IN THIS NOTE SHALL BE DEEMED OR OPERATE TO PRECLUDE THE HOLDER AND/OR ANY OTHER CREDITOR PARTY
FROM BRINGING SUIT OR TAKING OTHER LEGAL ACTION IN ANY OTHER JURISDICTION TO COLLECT THE OBLIGATIONS (AS DEFINED IN THE SECURITY
AGREEMENT), TO REALIZE ON THE COLLATERAL (AS DEFINED IN THE SECURITY AGREEMENT) OR ANY OTHER SECURITY FOR THE OBLIGATIONS, OR TO
ENFORCE A JUDGMENT OR OTHER COURT ORDER IN FAVOR OF THE HOLDER AND/OR ANY OTHER CREDITOR PARTY. THE COMPANY EXPRESSLY SUBMITS AND
CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND THE COMPANY HEREBY WAIVES ANY OBJECTION
WHICH IT MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE OR FORUM NON CONVENIENS. THE COMPANY HEREBY WAIVES PERSONAL
SERVICE OF THE SUMMONS, COMPLAINT AND OTHER PROCESS ISSUED IN ANY SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS,
COMPLAINT AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO THE COMPANY AT THE ADDRESS SET FORTH IN THE
PURCHASE AGREEMENT AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER OF THE COMPANY’S ACTUAL RECEIPT THEREOF
OR THREE (3) DAYS AFTER DEPOSIT IN THE U.S. MAILS, PROPER POSTAGE PREPAID.

 

    	 

    	-10-

    

 

(c)               
THE COMPANY HERETO WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE,
WHETHER ARISING IN CONTRACT, TORT, OR OTHERWISE BETWEEN THE HOLDER AND/OR ANY OTHER CREDITOR PARTY, ON THE ONE HAND, AND THE COMPANY,
ON THE OTHER HAND, ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM IN CONNECTION
WITH THIS NOTE, ANY OTHER RELATED AGREEMENT OR THE TRANSACTIONS RELATED HERETO OR THERETO.

 

5.10         
Severability. In the event that any provision of this Note is invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed
modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law
shall not affect the validity or enforceability of any other provision of this Note.

 

5.11         
Maximum Payments. Nothing contained herein shall be deemed to establish or require the payment of a rate of interest
or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid
or other charges hereunder exceed the maximum rate permitted by such law, any payments in excess of such maximum rate shall be
credited against amounts owed by the Company to the Holder and thus refunded to the Company.

 

5.12         
Security Interest. The Agent, for the ratable benefit of the Creditor Parties, has been granted a security interest
in certain assets of the Company as more fully described in the Security Agreement and the other Related Agreements.

 

5.13         
Construction; Counterparts. Each party acknowledges that its legal counsel participated in the preparation of this
Note and, therefore, stipulates that the rule of construction that ambiguities are to be resolved against the drafting party shall
not be applied in the interpretation of this Note to favor any party against the other. This Note may be executed by the parties
hereto in one or more counterparts, each of which shall be deemed an original and all of which when taken together shall constitute
one and the same instrument. Any signature delivered by a party by facsimile or electronic transmission shall be deemed to be an
original signature hereto.

 

5.14         
Certain Definitions. For purposes of this Note, the following terms shall have the following meanings:

 

(a)               
“Bloomberg” means Bloomberg, L.P.

 

(b)              
“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The
City of New York are authorized or required by law to remain closed.

 

(c)               
“Closing Sale Price” means, for any security as of any date, the last closing trade price for such security
on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and
does not designate the closing trade price (as the case may be) then last trade price of such security prior to 4:00:00 p.m., New
York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for
such security, the last trade price of such security on the principal securities exchange or trading market where such security
is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last trade price of such security in the over-the
counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no last trade price is reported
for such security by Bloomberg, the average of the ask prices of any market makers for such security as reported in the “pink
sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing Sale Price cannot be calculated for a security
on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market
value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market
value of such security, then such dispute shall be resolved in accordance with the procedures in Section 5.10. All such determinations
shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during such
period.

 

    	 

    	-11-

    

 

 

(d)              
 “Closing Date” shall be the date of Closing within the meaning set forth in the Purchase Agreement,
which date is the date the Company initially issued Notes pursuant to the terms of the Purchase Agreement.

 

(e)               
 “Eligible Market” means The New York Stock Exchange, the NYSE Amex, the Nasdaq Global Select Market,
the Nasdaq Global Market, the Nasdaq Capital Market or the Principal Market.

 

(f)               
 “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization, any other entity or a government or any department or agency thereof.

 

(g)               
“Principal Market” means the Over-the-Counter Bulletin Board of the Financial Industry Regulatory Authority,
Inc.

 

(h)              
“Required Holders” means the Holders, in the aggregate, holding at least a majority of the then-outstanding
Accreted Principal Amount of the Notes.

 

(i)                
“Trading Day” means, as applicable, (x) with respect to all price determinations relating to the Common
Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading
market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded,
provided that “Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange
or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on
such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange
or market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day
in writing by the Holder or (y) with respect to all determinations other than price determinations relating to the Common Stock,
any day on which The New York Stock Exchange (or any successor thereto) is open for trading of securities.

 

[Balance of page intentionally left blank;
signature page follows]

 

    	 

    	-12-

    

 

[Signature Page to Secured Convertible
Term Note]

 

IN WITNESS WHEREOF, the Company has
caused this Secured Convertible Term Note to be signed in its name effective as of this 3rd day of April, 2014.

 

HEALTHCARE CORPORATION OF AMERICA

 

By:

 

Name:

 

Title:

 

    	 

    	-13-

    

 

EXHIBIT I

 

CONVERSION NOTICE

 

Reference is made to the Secured Convertible
Note (the “Note”) issued to the undersigned by Healthcare Corporation of America (the “Company”).
In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the
Note) of the Note indicated below into shares of common stock, no par value (the “Common Stock”), of the Company,
as of the date specified below.

 

Date of Conversion:

 

Aggregate Conversion Amount to be converted:

 

Conversion Price:

 

Number of shares of Common Stock to be issued:

 

Please issue the Common Stock into which the
Note is being converted in the following name and to the following address:

 

 

 

Issue to:

 

Facsimile Number:

 

Holder:

 

By:

 

Title:

 

Dated:

 

Account Number:

(if electronic book entry transfer)

 

Transaction Code Number:

(if electronic book entry transfer)

 

Installment Amount(s) to be reduced (and corresponding
Installment Date(s)) and amount of reduction:

 

    	 

    	-14-

    

 

EXHIBIT II

 

ACKNOWLEDGMENT

 

The Company hereby acknowledges this Conversion
Notice and hereby directs _________________ to issue the above indicated number of shares of Common Stock in accordance with the
Transfer Agent Instructions dated _____________, 20__ from the Company and acknowledged and agreed to by ________________________.

 

 

HEALTHCARE CORPORATION OF AMERICA

 

By:

 

Name:

 

Title:THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR APPLICABLE STATE LAW. NEITHER
THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE LAW WHICH,
IN THE OPINION OF COUNSEL TO THE COMPANY, IS AVAILABLE.

 

WARRANT

 

For the Purchase of [____________] Shares
of Common Stock of

 

HEALTHCARE CORPORATION OF AMERICA

 

1.Grant of Warrant. THIS CERTIFIES
THAT, pursuant to the terms of that certain Note Purchase Agreement dated as of April 3, 2014 (the “NPA”), by
and among Healthcare Corporation of America, a Delaware corporation (the “Company”) and the Noteholders (as
defined in the NPA and hereinafter), and for consideration the sufficiency of which is hereby acknowledged, [_________________]
(“Holder” and together with its permitted transferees, the “Holders”) is entitled, at any
time or from time to time from the date hereof (the “Commencement Date”), and ending five (5) years from the
date hereof on April 2, 2019 (the ”Expiration Date”), but not thereafter, to subscribe for, purchase
and receive, in whole or in part, up to to purchase an aggregate of [_________] shares of common stock of the Company, par
value $0.0001 per share (the “Common Stock”), subject to adjustment as provided in Section 6 hereof. If the
Expiration Date is a day on which banking institutions are authorized by law to close in New York City, then this Warrant may be
exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the
Expiration Date, the Company agrees not to take any action that would terminate this Warrant. This Warrant is exercisable at an
exercise price equal to the lower among the following: (a) the price per share of the Next Round Securities (as defined in the
NPA); (b) the conversion price of a convertible note raised after the transaction contemplated herein and under the NPA; and (c)
the exercise price of warrants to the extent included in the Next Financing Round (as defined in the NPA) (the “Exercise
Price”).

 

2.Exercise.

 

2.1Exercise
Form. In order to exercise this Warrant, the exercise form attached hereto must be duly executed and completed and delivered
to the Company, together with this Warrant and payment of the Exercise Price for the shares of Common Stock being purchased payable
in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or official
bank check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration
Date, this Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and
expire.

 

2.2Cashless
Exercise. In lieu of exercising this Warrant by payment of cash or certified check or official bank check payable to the order
of the Company pursuant to Section 2.1 above, Holder may elect to receive the number of shares of Common Stock equal to the value
of this Warrant (or the portion thereof being exercised), by surrender of this Warrant to the Company, together with the exercise
form attached hereto, in which event the Company shall issue to Holder shares of Common Stock in accordance with the following
formula:

 

    	1

    	 

    

 

	X	=	Y(A-B)	 	 	 	 
	 	 	  A	 	 	 	 
	 	 	 	Where,	X	=	The number of shares of Common Stock to be issued to Holder;
	 	 	 	 	 	 	 
	 	 	 	 	Y	=	The number of shares of Common Stock for which the Warrant is being exercised;
	 	 	 	 	 	 	 
	 	 	 	 	A	=	The fair market value of one share of Common Stock; and
	 	 	 	 	 	 	 
	 	 	 	 	B	=	The Exercise Price.

 

 

For purposes of this
Section 2.2, the fair market value of a share of Common Stock is defined as follows:

 

(i)if the Company’s
Common Stock is traded on a securities exchange, the value shall be deemed to be the average of the closing prices on such exchange
or market over the thirty (30) day period ending three (3) days prior to the date of the exercise form being submitted in connection
with the exercise of the Warrant; or

 

(ii)if the Company’s
Common Stock is actively traded over-the-counter, the value shall be deemed to be the average of the closing bid prices over the
thirty (30) day period ending three (3) days prior to the date of the exercise form being submitted in connection with the exercise
of the Warrant; or

 

(iii)if there
is no active public market for the Common Stock, the value of a share of Common Stock shall be the fair market value thereof, as
determined in good faith by the Company’s Board of Directors.

 

2.3Legend. Each certificate for
the securities purchased under this Warrant shall bear a legend as follows unless such securities have been registered under the
Securities Act of 1933, as amended (the “Act”):

 

“THE SECURITIES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”)
OR APPLICABLE STATE LAW. NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED
EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT
AND APPLICABLE STATE LAW WHICH, IN THE OPINION OF COUNSEL TO THE COMPANY, IS AVAILABLE.”

  

3.Transfer.

 

3.1General Restrictions.
The registered Holder of this Warrant agrees by his, her or its acceptance hereof, that transfers to others may be made subject
to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver
to the Company the assignment form attached hereto duly executed and completed, together with this Warrant and payment of all transfer
taxes, if any, payable in connection therewith. The Company shall within five business days transfer this Warrant on the books
of the Company and shall execute and deliver a new Warrant or Warrants of like tenor to the appropriate assignee(s) expressly evidencing
the right to purchase the aggregate number of shares of Common Stock purchasable hereunder or such portion of such number as shall
be contemplated by any such assignment.

 

    	2

    	 

    

  

3.2Restrictions
Imposed by the Act. The securities evidenced by this Warrant shall not be transferred unless and until: (i) the Company has
received assurances from the Holder that the securities may be transferred pursuant to an exemption from registration under the
Act and applicable state securities laws, or (ii) a registration statement or a post-effective amendment to such Registration Statement
relating to the offer and sale of such securities has been filed by the Company and declared effective by the Securities and Exchange
Commission and compliance with applicable state securities law has been established.

 

4.Registration Rights. The Company
agrees to grant the Holder the same registration rights applicable in accordance with that certain Registration Rights Agreement,
dated as of December 2013, by and among the Company and the investors named therein, or if there exists a newer Registration Rights
Agreement, then the most recent version thereof.

 

5.New Warrants to be Issued.

 

5.1Partial Exercise
or Transfer. Subject to the restrictions in Section 3 hereof, this Warrant may be exercised or assigned in whole or in part.
In the event of the exercise or assignment hereof in part only, upon surrender of this Warrant for cancellation, together with
the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised pursuant
to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Warrant of like tenor to this
Warrant in the name of the Holder evidencing the right of the Holder to purchase the number of shares of Common Stock purchasable
hereunder as to which this Warrant has not been exercised or assigned.

 

5.2Lost Certificate.
Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Warrant and of
reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Warrant of like tenor
and date. Any such new Warrant executed and delivered as a result of such loss, theft, mutilation or destruction shall constitute
a substitute contractual obligation on the part of the Company.

 

6.Adjustments.

 

6.1Adjustments
to Exercise Price and Number of Securities. The Exercise Price and the number of shares of Common Stock underlying the Warrant
shall be subject to adjustment from time to time as hereinafter set forth:

 

6.1.1Equity
Financing. Reserved.

 

6.1.2Share Dividends;
Split Ups. If after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding shares of
Common Stock is increased by a stock dividend payable in shares of Common Stock or by a split up of shares of Common Stock or other
similar event, then, on the effective day thereof, the number of shares of Common Stock purchasable hereunder shall be increased
in proportion to such increase in outstanding shares, and the Exercise Price shall be proportionately adjusted.

 

    	3

    	 

    

  

6.1.3Aggregation
of Shares. If after the date hereof, and subject to the provisions of Section 6.3, the number of outstanding shares of Common
Stock is decreased by a consolidation, combination or reclassification of shares of Common Stock or other similar event, then,
on the effective date thereof, the number of shares of Common Stock purchasable hereunder shall be decreased in proportion to such
decrease in outstanding shares of Common Stock.

 

6.1.4Replacement
of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding shares of Common
Stock other than a change covered by Section 6.1.2 or 6.1.3 hereof or that solely affects the par value of the Common Stock, or
in the case of any share reconstruction or amalgamation or consolidation of the Company with or into another corporation (other
than a consolidation or share reconstruction or amalgamation in which the Company is the continuing corporation and that does not
result in any reclassification or reorganization of the outstanding shares of Common Stock), or in the case of any sale or conveyance
to another corporation or entity of the property of the Company as an entirety or substantially as an entirety in connection with
which the Company is dissolved, the Holder of this Warrant shall have the right thereafter (until the expiration of the right of
exercise of this Warrant) to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder immediately
prior to such event, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such
reclassification, reorganization, share reconstruction or amalgamation, or consolidation, or upon a dissolution following any such
sale or transfer, by a Holder of the number of shares of Common Stock obtainable upon exercise of this Warrant immediately prior
to such event; and if any reclassification also results in a change in shares of Common Stock covered by Section 6.1.2 or 6.1.3,
then such adjustment shall be made pursuant to Sections 6.1.2 or 6.1.3 and this Section 6.1.4. The provisions of this Section 6.1.4
shall similarly apply to successive reclassifications, reorganizations, share reconstructions or amalgamations, or consolidations,
sales or other transfers.

 

6.2Substitute
Warrant. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company with or into,
another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in any reclassification
or change of the outstanding Shares), the corporation formed by such consolidation or share reconstruction or amalgamation shall
execute and deliver to the Holder a supplemental Warrant providing that the holder of each Warrant then outstanding or to be outstanding
shall have the right thereafter (until the stated expiration of such Warrant) to receive, upon exercise of such Warrant, the kind
and amount of shares of stock and other securities and property receivable upon such consolidation or share reconstruction or amalgamation,
by a holder of the number of Shares of Common Stock and underlying securities of the Company for which such Warrant might have
been exercised immediately prior to such consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental
Warrant shall provide for adjustments which shall be identical to the adjustments provided for in this Section 6. The above provision
of this Section shall similarly apply to successive consolidations or share reconstructions or amalgamations.

 

6.3Elimination
of Fractional Interests. The Company shall not be required to issue certificates representing fractions of shares of Common
Stock upon the exercise of the Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests,
it being the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the
case may be, to the nearest whole number of shares of Common Stock or other securities, properties or rights.

 

7.Reservation. The Company shall
at all times reserve and keep available out of its authorized shares of Capital Stock, solely for the purpose of issuance upon
exercise of the Warrants, such number of shares of Common Stock or other securities, properties or rights as shall be issuable
upon the exercise thereof. The Company covenants and agrees that, upon exercise of the Warrants and payment of the Exercise Price
therefore, in accordance with the terms hereby, all shares of Common Stock and other securities issuable upon such exercise shall
be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder.

 

    	4

    	 

    

  

8.Certain Notice Requirements.

 

8.1Holders’
Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to
receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder
of the Company. If, however, at any time prior to the expiration of the Warrants and their exercise, any of the events described
in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event at least fifteen
days prior to the date fixed as a record date or the date of closing the transfer books for the determination of the shareholders
entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to vote on such
proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of the closing of
the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder a copy of each
notice given to the other shareholders of the Company at the same time and in the same manner that such notice is given to the
shareholders.

 

8.2Events Requiring
Notice. The Company shall be required to give the notice described in this Section 8 upon one or more of the following events:
(i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend or
distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings,
as indicated by the accounting treatment of such dividend or distribution on the books of the Company, (ii) the Company shall offer
to all the holders of its Shares any additional shares of capital stock of the Company or securities convertible into or exchangeable
for shares of capital stock of the Company, or any option, right or warrant to subscribe therefore, or (iii) a dissolution, liquidation
or winding up of the Company(other than in connection with a consolidation or share reconstruction or amalgamation) or a sale of
all or substantially all of its property, assets and business shall be proposed.

 

8.3Transmittal
of Notices. All notices, requests, consents and other communications under this Warrant shall be in writing and shall be deemed
to have been duly made when hand delivered, or mailed by express mail or private courier service: (i) if to the registered Holder
of the Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company, to following address
or to such other address as the Company may designate by notice to the Holders:

 

Healthcare Corporation
of America

Attention: Chief Executive
Officer

66 Ford Road

Denville, NJ 07834

 

With a copy to:

 

Loeb & Loeb LLP

345 Park Avenue

New York, New York 1015

Attention:  Mitchell
S. Nussbaum and Giovanni Caruso

 

    	5

    	 

    

  

9Miscellaneous.

  

9.1Amendments.
All modifications or amendments to this Warrant shall require the written consent of and be signed by the party against whom enforcement
of the modification or amendment is sought.

 

9.2Headings.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Warrant.

 

9.3Entire Agreement.
This Warrant (together with the other agreements and documents being delivered pursuant to or in connection with this Warrant)
constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements
and understandings of the parties, oral and written, with respect to the subject matter hereof.

 

9.4Binding Effect.
This Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their permitted assignees,
respective successors, legal representative and assigns, and no other person shall have or be construed to have any legal or equitable
right, remedy or claim under or in respect of or by virtue of this Warrant or any provisions herein contained.

 

9.5Governing
Law; Submission to Jurisdiction. This Warrant shall be governed by and construed and enforced in accordance with the laws of
the State of New York, without giving effect to conflict of laws principles thereof (other than sections 5-1401 and 5-1402 of the
New York General Obligations law, which shall apply to this Warrant). The Company hereby agrees that any action, proceeding or
claim against it arising out of, or relating in any way to this Warrant shall be brought and enforced in the New York Supreme Court,
County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such
jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and
that such courts represent an inconvenient forum. Any process or summons to be served upon the Company may be served by transmitting
a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth
in Section 8 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action,
proceeding or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover
from the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or
incurred in connection with the preparation therefore.

 

9.6Waiver, etc.
The failure of the Company or the Holder to at any time enforce any of the provisions of this Warrant shall not be deemed or construed
to be a waiver of any such provision, nor to in any way affect the validity of this Warrant or any provision hereof or the right
of the Company or any Holder to thereafter enforce each and every provision of this Warrant. No waiver of any breach, non-compliance
or non-fulfillment of any of the provisions of this Warrant shall be effective unless set forth in a written instrument executed
by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance
or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

 

 

[Remainder of page deliberately left
blank.]

 

 

 

 

    	6

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be signed by its duly authorized officer as of the 3rd day of April, 2014.

 

	 	HEALTHCARE CORPORATION OF AMERICA
	 	 	 
	 	By:	
	 	Name:	 
	 	Title:	 

 

ACCEPTED AND AGREED:

 

	[Noteholder] 	 
	 	 	 
	By:		 
	Name:	 	 
	Title:	 	 

 

 

    	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]